---
title: "Kodiak Sciences tumbles 8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305694202.md"
description: "Kodiak Sciences fell 7.91% to US$102.40. Up 176.61% over six months and up 266.24% YTD."
datetime: "2026-11-16T15:16:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305694202.md)
  - [en](https://longbridge.com/en/news/305694202.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305694202.md)
generator: "portal-rs"
---

# Kodiak Sciences tumbles 8%

Kodiak Sciences (KOD.US) tumbled nearly **8%** during regular trading to **$102.40**.

The stock is up 176.61% over the past six months and up 266.24% year to date. Volume was 4.32 times its average.

The Nasdaq Composite is down 2.41% over the past five sessions and up 6.03% year to date.

The company reported a third-quarter net loss of $66.2 million, with GAAP and basic loss per share at $1.05, exceeding the LSEG consensus by $0.01. The wider year-over-year loss was primarily driven by increased research and development expenses for clinical trials.

Kodiak held $88.7 million in cash as of quarter-end and raised an additional $69.0 million through equity financing after the period, funds expected to support operations into 2027. On the pipeline front, the company plans to submit a Biologics License Application for Zenkuda by year-end and will announce initial Phase III results for KSI-101 in December 2026.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [KOD.US](https://longbridge.com/en/quote/KOD.US.md)

## Related News & Research

- [Kodiak Sciences GAAP EPS of -$1.05 beats by $0.01](https://longbridge.com/en/news/305374957.md)
- [Did Phase 3 Eye Drug Results Just Shift Kodiak Sciences (KOD) Investment Narrative?](https://longbridge.com/en/news/305493238.md)
- [KOD: Zenkuda’s BLA, KSI-101’s PEAK 1 readout and accelerating KSI-501 trials define the near-term milestones](https://longbridge.com/en/news/305683102.md)
- [JP Morgan maintains Kodiak Sciences at Overweight, raises price target to $128 from $124](https://longbridge.com/en/news/306164192.md)
- [Kodiak Sciences (KOD) Could Be 23% Undervalued On Its Retina Pipeline Story](https://longbridge.com/en/news/304752600.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**